Skip to content
Screener

Cash & Equivalents at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
$141.8M-78.1%
Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
$14.1M-26.8%
Sotera Health logo
Sotera HealthSHC
$356.72M+7.3%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
$172.02M-31.6%
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
$168.6M+108%
Revvity logo
RevvityRVTY
$861.47M-24.3%

Other financials

Income statement

See full
Revenue$1.0B-2.7%
Gross profit$349.0M-3.5%
Operating income$119.9M+19.7%
Net income-$1.5M-103%
EPS (diluted)-$0.03-103%

Balance sheet

See full
Total debt$3.0B+8.1%
Total equity$2.8B-15.3%
Total assets$7.5B-0.4%

Cash flow

See full
Operating cash flow$179.7M-12.2%
CapEx$31.1M-11.9%
Free cash flow$148.6M-12.2%

Valuation

See full
Market cap$12.56B+70.1%
Enterprise value$15.36B+53.4%
P/S3.1×+1.3×

Profitability

See full
Gross margin84.7%
Operating margin13%-2.4pp
Net margin-6%
FCF margin9.3%-5.1pp

Returns & leverage

See full
Return on equity-7.7%
Debt / equity1.1×+0.2×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 9:21 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001100682-26-000118
Line itemSix Months Ended / June 27, 2026Six Months Ended / June 28, 2025
Purchase of remaining equity interests of other redeemable noncontrolling interest(19,140)
Other, net(2,607)(6,458)
Net cash provided by (used in) financing activities183,063(332,246)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash46717,934
Net change in cash, cash equivalents, and restricted cash24,584(20,830)
Cash, cash equivalents, and restricted cash, beginning of period215,997205,570
Cash, cash equivalents, and restricted cash, end of period$240,581$184,740
See Notes to Unaudited Condensed Consolidated Financial Statements.

Item 1. Financial Statements

FAQ

What is Charles River Laboratories's cash & equivalents?
Charles River Laboratories (CRL) reported cash & equivalents of $240.58M in Q2 2026.
How has Charles River Laboratories's cash & equivalents changed year-over-year?
Charles River Laboratories's cash & equivalents increased by 30.2% year-over-year, from $184.74M to $240.58M.
What is the long-term trend for Charles River Laboratories's cash & equivalents?
Over 5 years (2020 to 2025), Charles River Laboratories's cash & equivalents has grown at a -1.5% compound annual growth rate (CAGR), from $233.12M to $216M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Charles River Laboratories's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude